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We report that cryoablation of primary tumors synergizes with anti-CTLA-4 treatment to mediate rejection of secondary
tumors in the TRAMP mouse model of prostate cancer. T cells, in particular CD8
+ T cells specific for the TRAMP antigen
SPAS-1, were enriched in both secondary tumors and spleens of combination-treated mice.
The recently FDA approved immuno-
therapy, Ipilimumab (commercial name
Yervoy) is a fully human monoclonal
antibody that blocks the function of
CTLA-4, an inhibitory receptor expressed
by T cells. CTLA-4 is expressed and
trafficked to the T-cell surface upon
activation, and blockade of this check-
point pathway, through administration of
monoclonal antibodies, induces antitumor
immunity by promoting T-cell survival
and proliferation.
1 In clinical trials,
Ipilimumab improved overall survival time
of metastatic melanoma patients compared
with control groups.
2,3 Studies in mouse
models, using a monoclonal antibody that
blocks the function of mouse CTLA-4,
showed that treatment with CTLA-4
blockade as a single agent results in
the rejection of immunogenic tumors.
4
However, rejection of less immunogenic
tumors can beachieved only when CTLA-4
blockade is combined with immunothera-
pies such as those that induce increased
antigen uptake and presentation on MHC
Class I molecules (a process called “cross-
presentation”) by professional antigen-
presenting cells (APCs). These types of
therapies include GM-CSF secreting
whole tumor cell vaccines,
5 radiation
6 or
a FLT-ligand expressing vaccine.
7 It is
reasonable to hypothesize that in humans,
similar combination therapies administered
in conjunction with Ipilimumab may boost
their effectiveness and increase survival time
in a larger fraction of patients. While this
hypothesis is currently being tested in
clinical trials combining the use of a GM-
CSF-expressing tumor cell vaccine (GVAX)
with Ipilimumab,
8 we wanted to investigate
whether this was also true when anti-
CTLA-4 was combined with tumor abla-
tion techniques. Local tumor ablation,
such as cryoablation, has occasionally
been shown to lead regression of tumor
metastases, a phenomenon that could likely
be attributed to a systemic anti-tumor
immune response resulting from increased,
albeit in most cases still insufficient,
antigen cross-presentation by professional
APC. Starting from the assumption that
cryoablation would increase cross-presenta-
tion, we hypothesized that administration
of anti-CTLA-4 during the destruction of
a primary tumor, through cryoablation,
would further improve the generation a
systemic immune response that would
result in the eradication of metastatic
disease.
9 The possibility of combining
anti-CTLA-4 therapy with cryotherapy
is appealing because of the low mor-
bidity and cost-effectiveness of such an
ablative technique compared with surgical
interventions.
Using the transplantable TRAMP model
of mouse prostate cancer, we developed a
unique system to study the induction of
systemic immunity and rejection of a
secondary tumor challenge in mice treated
with anti-CTLA-4 and cryoablation com-
bination therapy. Our previous work in the
TRAMP model led to the discovery of
the CD8
+ T-cell tumor antigen SPAS-1,
which contains a mutation in its antigenic
epitope.
10 SPAS-1 was identified as the
target of a T cell line derived from the
spleen and lymph nodes of mice that
received a tumor-rejecting immunotherapy:
anti-CTLA-4 and GM-CSF-expressing
TRAMP cell vaccine. By this method,
SPAS-1 was defined due to its highly
immunogenic character and was found to
be the immunodominant TRAMP antigen.
This finding has enabled us to track
the specific CD8
+ T-cell response in the
TRAMP model through the use of MHC
Class I tetramers and ELISPOT assays.
TRAMP C2 tumors were implanted on the
left flank of male mice and cryoablated
when they reached about 5–8m mi n
diameter. The mice were then treated
with anti-CTLA-4 and rechallenged with a
second inoculation of TRAMP C2 on the
opposite flank. Strikingly, in mice that
received both anti-CTLA-4 and cryoabla-
tion, the number of SPAS-1-specific CD8
+
T cells per mg of tumor was significantly
increased compared with control mice.
Furthermore, the SPAS-1-specific T cells
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Figure1. For figure legend, see page 546.
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were enriched in the spleens of the mice
receiving the combination treatment, indic-
ating the induction of a systemic tumor-
specific immune response. Importantly,
the combination of anti-CTLA-4 in vivo
blockade and cryoablation also resulted in
improved survival and in an increased
percentage of secondary tumor rejection.
Examination of secondary tumors by his-
tology and flow cytometry revealed that,
compared with controls, tumors from
combination treated mice exhibited a shift
from an immunologically hostile micro-
environment with few CD4
+ and CD8
+
T cells and a low effector to T regulatory
cell ratio to an immunologically permis-
sive microenvironment where tumors were
highly infiltrated by effector T cells and
the ratio of effector to T regulatory cell
was high. Furthermore, CD8
+ T cells were
important for tumor rejection as their
depletion resulted in a decreased effect of
the combination therapy.
Although the full mechanism of tumor
immunity in our model has not been
elucidated, it likely involves the exertion
of effector function of TRAMP-specific
T cells after their activation by activated
APCs. Neither cryoablation nor CTLA-4
blockade on their own were sufficient to
mediate rejection of secondary tumors
(Fig.1). Therapies such as vaccines, chemo-
therapies, and radiotherapy that improve
antigen cross-presentation may be the most
effective treatments to combine with CTLA-
4 blockade and we speculate that cryoabla-
tion synergizes with CTLA-4 blockade by
augmenting antigen cross-presentation.
Another possible mechanism is that while
a growing intact tumor is likely to have a
low level of antigen release in the absence
of cryoablation, removal of the primary
tumor may result in the removal of a
systemic immune suppressive environ-
ment. While future studies will delineate
the mechanisms by which cryoablation
cooperates with CTLA-4 blockade to
generate systemic immunity, our current
work provides evidence that this com-
bination therapy may improve survival in
patients with metastatic disease.
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Figure1 (See previous page). Cryoablation needs to be combined with CTLA-4 blockade to generate systemic immunity of sufficient strength to
reject a secondary tumor. (A) A primary TRAMP C2 tumor is inoculated into the left flank of a mouse and allowed to grow until it is large enough to
cryoablate. Our model proposes that cryoablation results in the release of antigens, which are taken up by antigen presenting cells (cross-presentation).
In the presence of CTLA-4 blockade, SPAS-1 specific T cells maximally proliferate in response to positive signals delivered by the engagement of T cell
receptor with SPAS-1 peptide/MHC I complex and CD28 with B7. This enhanced proliferation results in the rejection of a secondary right flank tumor.
(B) In the absence of CTLA-4 blockade, CTLA-4 dampens T cell proliferation and a second tumor grows uncontrolled. (C) In absence of cryoablation,
diminished antigen cross-presentation results in limited cross-priming of SPAS-1 specific T cells. Even in the presence CTLA-4 blockade, proliferation
of SPAS-1 specific T cells is insufficient to mediate rejection of the tumor.
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